Finland-based FIT Biotech will begin recruiting 1,000 patients for a trial of its therapeutic HIV vaccine later this year. If successful the trial--which is due to last two to three years--will culminate in marketing applications to U.S. and European regulators. FIT Biotech thinks the vaccine can cut the viral load in patients with HIV, potentially reducing the need to use costly and arduous antiretrovirals. Article